Vivian Paintsil1, Haileyesus David2, Joyce Kambugu3, Lorna Renner4, Francine Kouya5, Tim Eden6, Peter Hesseling7, Elizabeth Molyneux8, Trijn Israels9. 1. Dept of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana. 2. Dept of Paediatric Oncology, Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. 3. Dept of Paeds Oncology, Uganda Cancer Institute, Kampala, Uganda. 4. Dept of Child Health, University of Ghana Medical School, Accra, Ghana. 5. Dept of Paediatric Oncology, Mbingo Baptist Hospital, Cameroon. 6. Acad Unit of Paediatric and Adolescent Oncology, University of Manchester, UK. 7. Dept of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa. 8. Dept of Paediatrics, College of Medicine, Blantyre, Malawi. 9. Dept of Paediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands; Co-chair International Society of Pediatric Oncology (SIOP) Pediatric Oncology in Developing Countries (PODC). Electronic address: t.israels@vumc.nl.
Abstract
AIM: Reported survival of Wilms tumour in sub-Saharan Africa is below 50%. A published International Society of Pediatric Oncology (SIOP) Pediatric Oncology in Developing Countries (PODC) consensus adapted treatment guideline is implemented as a multi-centre prospective clinical trial at eight centres in sub-Saharan Africa. A baseline evaluation has been done to help decide on priorities to improve outcome and to assess improvements over time. METHODS: A retrospective chart review was performed of patients admitted with Wilms tumour in the three years (2011-2013) preceding the collaborative trial. Patient outcome at the end of treatment was documented for all patients diagnosed in 2011 and 2012. Outcome was classified as (1) alive, no evidence of disease; (2) alive with disease; (3) died during treatment and (4) incomplete treatment. Details on treatment facilities, staff and estimated cost of treatment are documented. RESULTS: Every year 114-130 patients are diagnosed. The mean survival at end of treatment is 39% (69/176) ranging from 11% to 61%. Incomplete treatment is the most common cause of treatment failure with 31% (54/176), ranging from 14% to 48% between centres. Twenty-six percent (46/176) of patients died during treatment, ranging from 13% to 37%. Estimated cost of treatment for parents ranged from 100 US$ to 1100 US$ and was considered an important cause of failure to complete treatment. CONCLUSION: Overall two year survival is estimated at 25%. Prevention of incomplete treatment is possible and will positively affect outcome. Sharing similar local challenges in this regional collaborative project helps to identify and implement feasible, sustainable and successful strategies.
AIM: Reported survival of Wilms tumour in sub-Saharan Africa is below 50%. A published International Society of Pediatric Oncology (SIOP) Pediatric Oncology in Developing Countries (PODC) consensus adapted treatment guideline is implemented as a multi-centre prospective clinical trial at eight centres in sub-Saharan Africa. A baseline evaluation has been done to help decide on priorities to improve outcome and to assess improvements over time. METHODS: A retrospective chart review was performed of patients admitted with Wilms tumour in the three years (2011-2013) preceding the collaborative trial. Patient outcome at the end of treatment was documented for all patients diagnosed in 2011 and 2012. Outcome was classified as (1) alive, no evidence of disease; (2) alive with disease; (3) died during treatment and (4) incomplete treatment. Details on treatment facilities, staff and estimated cost of treatment are documented. RESULTS: Every year 114-130 patients are diagnosed. The mean survival at end of treatment is 39% (69/176) ranging from 11% to 61%. Incomplete treatment is the most common cause of treatment failure with 31% (54/176), ranging from 14% to 48% between centres. Twenty-six percent (46/176) of patients died during treatment, ranging from 13% to 37%. Estimated cost of treatment for parents ranged from 100 US$ to 1100 US$ and was considered an important cause of failure to complete treatment. CONCLUSION: Overall two year survival is estimated at 25%. Prevention of incomplete treatment is possible and will positively affect outcome. Sharing similar local challenges in this regional collaborative project helps to identify and implement feasible, sustainable and successful strategies.
Authors: K Ford; S Gunawardana; E Manirambona; G S Philipoh; B Mukama; A Kanyamuhunga; P Cartledge; M J Nyoni; D Mwaipaya; J Mpwaga; Z Bokhary; T Scanlan; T Heinsohn; H Hathaway; R Mansfield; S Wilson; K Lakhoo Journal: World J Surg Date: 2020-01 Impact factor: 3.352
Authors: Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Festus Njuguna; Hugo A Martijn; Robert Tenge Kuremu; Peter Saula; Patel Kirtika; Gilbert Olbara; Sandra Langat; Steve Martin; Jodi Skiles; Terry Vik; Gertjan J L Kaspers; Saskia Mostert Journal: J Glob Oncol Date: 2016-12-21
Authors: James R Young; Hendry Robert Sawe; Juma A Mfinanga; Ernest Nshom; Ethan Helm; Charity G Moore; Michael S Runyon; Stacy L Reynolds Journal: BMJ Open Date: 2017-07-10 Impact factor: 2.692